Accuray cyberknife® robotic radiotherapy platform expands range of neurological indications that can be effectively treated with stereotactic radiosurgery

Sunnyvale, calif., nov. 10, 2021 /prnewswire/ -- accuray incorporated (nasdaq: aray) announced today that more than two decades of globally-driven clinical data support the use of the company's cyberknife ® robotic radiotherapy platform for the delivery of stereotactic radiosurgery (srs) treatments for neurological diseases.
ARAY Ratings Summary
ARAY Quant Ranking